Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.

Pulmonary arterial hypertension (PAH) carries a high morbidity and mortality burden in Systemic Sclerosis (SSc). Therefore, PAH screening and early detection are pivotal. A systematic literature review (SLR) to search for all screening tools and modalities for SSc-PAH was performed in reference to right heart catheterization as diagnostic gold standard. Papers from 2 previously published SLRs and derived from a systematic search on Pubmed, EMBASE, Web of Science for papers published from 03/10/2017 to 31/12/2018 were manually included. A total of 199 papers were reviewed and 32 were extracted, with a low bias risk according to QUADAS2. Echocardiography, pulmonary function tests, clinical features and serum biomarkers were the most frequently tools used for screening, with different parameters combined in a variable fashion, as single item or as part of composite algorithms. Among the composite algorithms, the DETECT score, ESC/ERS 2009 or 2015 guidelines, ASIG and ITINER-air algorithms were the most commonly used in a wide range of patients. In different cohorts, DETECT and ASIG showed higher sensitivity and negative predictive value than ESC/ERS 2009. In conclusion, the literature shows echocardiography as the leading screening tool for SSc-PAH. In particular, systolic pulmonary arterial pressure (sPAP) and tricuspid regurgitation velocity (TRV), both as single items or part of composite algorithms, including also serum biomarkers, clinical and functional items, are the most frequent parameters evaluated.
Competing Interests: Declaration of Competing Interest CB received honoraria from Actelion and Eli-Lilly; GDL received honoraria from SOBI, Novartis, Pfizer, MSD, Celgene; MGL: none; EZ: received consultancy fee from GlaxoSmithKline; GL: none; PA received consultancy and/or travel expenses from Bristol-Myers-Squibb, CSL Behring, Janssen, Novartis, Pfizer, Roche, SOBI; LD received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. AD received honoraria/speaking fees from GSK, Eli-Lilly, Roche, Janssen, Pfizer; MMC reports receipt of grant/research support and/or speaker's bureau attendance from Actelion, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Bayer - MSD, Biogen Italia, Eli Lilly.
(Copyright © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)